Will Magioncalda is an associate in the firm’s Business Law Department and a member of its Technology and Life Sciences groups.

Mr. Magioncalda represents clients across the life sciences and technology industries, which include global investment banks as well as public and private companies.

His work extends to every stage of the corporate life cycle from financing through successful initial public offering or acquisition, with a focus on public and private capital markets transactions such as IPOs, follow-on offerings and private placements of equity and debt securities. He also counsels clients on a wide array of corporate matters including mergers and acquisitions, securities law compliance, and corporate governance.

Experience

工作经历

EXPÉRIENCE

ERFAHRUNG

A selection of Mr. Magioncalda’s recent representations include:

Initial Public Offerings and Follow-on Offerings

  • The underwriters in Royalty Pharma plc’s $2.5 billion initial public offering and $728 million secondary follow-on offering
  • Moderna, Inc. in its $1.34 billion and $500 million public follow-on offerings
  • The underwriters in Exscientia’s $350.4 million initial public offering and concurrent $160 million private placements
  • The underwriters in Sarepta Therapeutics’ $575 million public follow-on offering
  • The underwriters in Krystal Biotech’s $200 million and $125 million public follow-on offerings
  • The underwriters in Omega Therapeutic’s $144.6 million initial public offering
  • The underwriters in Ambrx Biopharma’s $126 million initial public offering
  • The underwriters in Valneva SE’s $107.6 million initial public offering and $102 million public follow-on offering
  • Codiak BioSciences in its $82.5 million initial public offering and $66.4 million public follow-on offering
  • HOOKIPA Pharma, Inc. in its $84 million initial public offering
  • The underwriters in Repare Therapeutics, Inc.’s $253 million initial public offering and $101.2 million public follow-on offering
  • The underwriters in Harmony Biosciences’ $147.6 million initial public offering
  • The underwriters in Pandion Therapeutics’ $135 million initial public offering
  • Goldman Sachs & Co. and other underwriters in Arvinas, Inc.’s $120 million initial public offering and $150 million and $400 million public follow-on offerings
  • The underwriters in Immunomedics, Inc.’s $420 million and $285 million public follow-on offerings

Other Corporate Transactions

  • GameChange Solar in its $150 million preferred stock financing 
  • The initial purchasers in Royalty Pharma’s $6 billion and $1.3 billion offerings of its convertible senior notes
  • Foundation Medicine, Inc. in connection with its merger with Roche at an enterprise valuation of $5.3 billion
  • The initial purchasers in Dynavax Technologies’ $200 million offering of its convertible senior notes
  • Galecto in its $50 million “at-the-market” offering
  • Cowen as sales agent in multiple ATM facilities, including for Albireo Pharma, Ovid Therapeutics, Syndax Pharmaceuticals and Dynavax Technologies
  • Akili Interactive Labs, Inc. in its $55 million Series C financing
  • Even Financial, Inc. in its $25 million Series B financing and $18 million Series A financing
  • Aircall.io, Inc. in its $29 million Series B financing
Professional Experience

Prior to joining Goodwin, Mr. Magioncalda was an associate at Cravath, Swaine & Moore LLP in New York.

In The News

相关新闻

ACTUALITÉS

MELDUNGEN

Credentials

专业资格

RÉFÉRENCES

WERDEGANG

Education

J.D., 2015
University of Virginia School of Law
B.S.F.S., 2010
Georgetown University

Admissions

Bar

New York
Profile Image
Get In Touch
联系我们
NOUS CONTACTER
Kontakt
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
搜寻其他律师
Recherche par Pratique
ANWALTSSUCHE